Skip to main content
Premium Trial:

Request an Annual Quote

James Smith, John Quackenbush, Chad Richards, Walter Bodmer, David Arnold, Douglas Rex

Orchid Cellmark has named James Smith to the post of VP and CFO. Smith formerly was executive VP and CFO of Aphton, and before that he was VP and global controller of Ansell/Smith. He also served as a senior executive in finance and accounting at Wyeth and American Cyanamid Company.

John Quackenbush has joined Dermtech’s scientific advisory board. Quackenbush is a professor of biostatistics and computational biology at the Dana-Farber Cancer Institute and a professor of computational biology and bioinformatics at the Harvard School of Public Health.

Transgenomic has named Chad Richards as senior VP of sales and marketing. Richards formerly was national sales director of the Cancer Diagnostics Division for Quest Diagnostics, and before that he was involved in sales and marketing at Ventana Medical Systems.

Oxford Genome Sciences has added Walter Bodmer to its scientific advisory board. Bodmer is head of the Cancer and Immunogenetics laboratory in the Weatherall Institute of Molecular Medicine at the University of Oxford. Bodmer formerly was director general of the Imperial Cancer Research Fund for a dozen years, and before that he was a professor of genetics at Oxford.

Third Wave Technologies has appointed David Arnold to its board of directors. Arnold is a former VP and CTO of Kennametal, where he worked for 24 years.

Epigenomics has named the first members for its new colorectal cancer medical advisory board. Appointees include Douglas Rex, professor of medicine at Indiana University’s School of Medicine; Philip Schoenfeld, associate professor in the department of internal medicine at the University of Michigan’s School of Medicine; Deborah Fisher, assistant professor of medicine at Duke University; and Scott Ramsey, associate professor of medicine and health services at the Fred Hutchinson Cancer Research Center.

Filed under

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.